R. Corre

9.9k total citations
88 papers, 1.0k citations indexed

About

R. Corre is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, R. Corre has authored 88 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 14 papers in Surgery. Recurrent topics in R. Corre's work include Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Diagnosis and Treatment (21 papers). R. Corre is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Diagnosis and Treatment (21 papers). R. Corre collaborates with scholars based in France, United States and Spain. R. Corre's co-authors include C. Chouaïd, Vincent Cottin, Thierry Chinet, A. Lavolé, Éric Marchand, Jean-François Cordier, Martine Reynaud‐Gaubert, Henri Plauchu, A. Vergnenègre and Laurent Greillier and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

R. Corre

78 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Corre France 17 816 541 149 113 102 88 1.0k
Luc Thiberville France 11 597 0.7× 427 0.8× 88 0.6× 85 0.8× 73 0.7× 35 856
Mohamed Amine Bayar France 11 425 0.5× 390 0.7× 92 0.6× 176 1.6× 100 1.0× 20 729
Katarzyna Pogoda Poland 11 392 0.5× 512 0.9× 118 0.8× 176 1.6× 44 0.4× 53 721
Raphael Brandão Moreira United States 11 369 0.5× 504 0.9× 50 0.3× 99 0.9× 83 0.8× 30 719
Charles Ricordel France 14 529 0.6× 467 0.9× 42 0.3× 81 0.7× 60 0.6× 74 787
Sonia Yip Australia 14 361 0.4× 308 0.6× 56 0.4× 83 0.7× 83 0.8× 75 662
Shimao Fukai Japan 16 820 1.0× 442 0.8× 72 0.5× 81 0.7× 208 2.0× 48 1.0k
Cheryl Pugh United Kingdom 10 970 1.2× 619 1.1× 222 1.5× 43 0.4× 124 1.2× 17 1.1k
M. Puglisi Italy 16 408 0.5× 539 1.0× 55 0.4× 68 0.6× 91 0.9× 38 998
Keita Kudo Japan 13 611 0.7× 1.0k 1.9× 59 0.4× 107 0.9× 122 1.2× 35 1.3k

Countries citing papers authored by R. Corre

Since Specialization
Citations

This map shows the geographic impact of R. Corre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Corre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Corre more than expected).

Fields of papers citing papers by R. Corre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Corre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Corre. The network helps show where R. Corre may publish in the future.

Co-authorship network of co-authors of R. Corre

This figure shows the co-authorship network connecting the top 25 collaborators of R. Corre. A scholar is included among the top collaborators of R. Corre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Corre. R. Corre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vergnenègre, A., I. Monnet, Charles Ricordel, et al.. (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 178. 191–197. 5 indexed citations
2.
Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations
3.
Scherpereel, Arnaud, É. Martin, L. Brouchet, et al.. (2023). Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer. Lung Cancer. 177. 21–28. 5 indexed citations
4.
Ricordel, Charles, Marc Aubry, Florence Jouan, et al.. (2023). Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. Scientific Reports. 13(1). 3626–3626. 4 indexed citations
5.
Chouaïd, C., R. Corre, Matteo Giaj Levra, et al.. (2022). Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clinical Cancer Informatics. 6(6). e2100108–e2100108. 6 indexed citations
6.
Corre, R., et al.. (2020). Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC. Journal of Thoracic Oncology. 15(8). e147–e148. 3 indexed citations
7.
8.
Levra, Matteo Giaj, François-Emery Cotté, R. Corre, et al.. (2019). MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S274–S275. 2 indexed citations
9.
Assié, Jean‐Baptiste, François-Emery Cotté, Matteo Giaj Levra, et al.. (2019). P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S708–S708. 1 indexed citations
10.
11.
Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases. Journal of Thoracic Oncology. 13(10). S384–S385. 10 indexed citations
12.
Halmos, Balázs, Alexander Luft, Margarita Majem, et al.. (2018). MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S391–S391. 4 indexed citations
13.
Zalcman, Gérard, Julien Mazières, Laurent Greillier, et al.. (2017). Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Annals of Oncology. 28. v648–v648. 12 indexed citations
14.
Besse, Benjamin, Sylvestre Le Moulec, Julien Mazières, et al.. (2017). P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1. Journal of Thoracic Oncology. 12(1). S1085–S1086. 1 indexed citations
15.
16.
Cabillic, Florian, Audrey Gros, Frédéric Dugay, et al.. (2014). Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances. Journal of Thoracic Oncology. 9(3). 295–306. 118 indexed citations
17.
Peyronnet, B., R. Corre, H. Léna, et al.. (2014). Surrénalectomie pour métastases surrénaliennes : la voie d’abord laparoscopique est-elle bénéfique pour tous les patients ?. Progrès en Urologie. 24(16). 1069–1075. 4 indexed citations
18.
19.
Millet, Arnaud, et al.. (2008). Faux anévrisme de l’artère pulmonaire sur récidive de cancer. La Presse Médicale. 37(12). 1817–1819. 2 indexed citations
20.
Cottin, Vincent, Thierry Chinet, A. Lavolé, et al.. (2007). Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. Medicine. 86(1). 1–17. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luc Thiberville Breakdown of academic impact, for papers by Mohamed Amine Bayar Breakdown of academic impact, for papers by Katarzyna Pogoda Breakdown of academic impact, for papers by Raphael Brandão Moreira Breakdown of academic impact, for papers by Charles Ricordel Breakdown of academic impact, for papers by Sonia Yip Breakdown of academic impact, for papers by Shimao Fukai Breakdown of academic impact, for papers by Cheryl Pugh Breakdown of academic impact, for papers by M. Puglisi Breakdown of academic impact, for papers by Keita Kudo
Rankless by CCL
2026